Our PAINT-2D proprietary platform employs various approaches to functionally assess the immunomodulatory activity of small and large molecules in cells from immune linages, including T cells, monocytes, macrophages, dendritic cells and tumor infiltrating lymphocytes (TILs). This platform not only allows us to efficiently screen and optimize the best candidates for immune-oncology but also provides a tool to effectively evaluate combination potentials between different agents, which in the past has to primarily rely on costly clinical trials. Adlai Nortye is utilizing PAINT-2D platform to power our internal R&D to address major challenges we are facing in battling against cancer.
Our ANEAT-Id technology is a highly efficient and robust yeast display system that is dedicated to therapeutic antibody discovery and development. It features 1) a super-size human antibody library; 2) high display efficiency; 3) a display/secretion switchable design; and 4) various developability assessment tools. Adlai Nortye is utilizing ANEAT-Id technology to facilitate and accelerate therapeutic antibody R&D.